No ‘easy’ weight loss: don’t ignore the societal impact of anti-obesity medications
The introduction of a new set of drugs that suppress appetite — such as semaglutide, marketed as Ozempic and WeGovy by the Danish company Novo Nordisk — has led to an increase
